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Abstract: Zonisamide (ZNS) efﬁ  cacy and safety in epilepsy have been demonstrated in four 
double-blind, placebo-controlled studies. In the present article, we examined all long-term 
studies performed with this drug. Nine open-label studies, in which ZNS had been administered 
as an add-on or as monotherapy to epileptic patients for at least 6 months, were selected for 
our analysis. Four outcome measures were searched. Retention of this drug after 1 year varied 
between 45% and 65%. The percentages of patients achieving a 50% seizure reduction, with 
respect to baseline, ranged between 37% and 65%. In patients with drug-resistant forms of 
epilepsy, the percentage of patients reaching a 6-month seizure freedom period was 9%. The 
percentages of patients who discontinued the experimental drug due to adverse effects ranged 
between 4% and 24%. Somnolence and dizziness were the most frequently reported adverse 
effects. Long-term studies demonstrate that ZNS has a good efﬁ  cacy and tolerability proﬁ  le, 
and support its use as adjunctive therapy for epileptic patients.
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Introduction
Zonisamide (ZNS) is a new antiepileptic drug (AED) that has been approved for broad 
use in Japan, while regulatory agencies in the USA and Europe have approved it only 
as an adjunctive therapy for treatment of partial seizures in adults.
This drug is a benzisoxazole derivative, ﬁ  rst synthesized in 1972, and is structur-
ally different from all other AEDs.1 Its anticonvulsant activity, which was fortuitously 
discovered, has been proven in a number of experimental seizure models.1 Current 
evidence suggests that ZNS has multiple modes of action. It exerts its pharmacological 
effects by blockade of neuronal voltage-gated sodium channels and low-voltage-
activated (T-type) calcium channels.2 A modest inhibitory effect on carbonic anhydrase 
has been reported, which is thought to be 100 to 200 times less potent than that of acet-
azolamide. This mechanism is not believed to signiﬁ  cantly contribute to the antiepileptic 
actions of the drug.3 ZNS has also some effects on the synthesis, release, and degradation 
of a number of different neurotransmitters, including glutamate, GABA, dopamine, 
serotonin, and acetylcholine which may lead to enhancement of synaptic inhibition.4
Several in vitro experiments have shown that ZNS has some neuroprotective effects 
that may suggest a potential use in treating subjects with traumatic brain injury.5
ZNS has a favorable pharmacokinetic proﬁ  le. It is rapidly absorbed from the 
gastrointestinal tract, and peak plasma concentrations are achieved within 2 to 5 hours 
after oral dosing. Food can reduce the rate, but not the extent, of absorption. Oral 
bioavailability approaches 100%, and the kinetics are linear after the administration 
of a single dose of 100 to 800 mg.6
Although inactivation of ZNS occurs predominantly by hepatic metabolism 
involving CYP3A4-mediated reduction, this drug neither induces nor inhibits the 
hepatic cythochrome P450 isoenzymes that are implicated in the metabolism of Neuropsychiatric Disease and Treatment 2009:5 250
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several AEDs.7 ZNS clearance increases to about 50% when 
administered in combination with other AEDs that are known 
inducers of CYP3A4, such as phenobarbital (PB), carbamaze-
pine (CBZ), or phenytoin (PHT). However, since the half-life 
of ZNS is 50 to 70 hours in non-induced subjects,8,9 a slight 
increase of ZNS metabolism is not expected to have any 
signiﬁ  cant clinical effect. Nevertheless, if discontinuation 
of a co-administered, inducing AED is planned, the dose of 
ZNS should be adapted appropriately.
Finally, experimental data revealed only modest differ-
ences in the most relevant kinetic ZNS parameters between 
adults and special populations of young or old healthy 
volunteers.9,10
ZNS efﬁ  cacy and safety have been demonstrated in 
several pre-registration, randomized, double-blind, placebo-
controlled studies in which this drug was administered as 
adjunctive therapy in drug-resistant epileptic patients.11–14 
Results of these studies have been the object of several 
reviews and meta-analyses.15,16
The transferability of these ﬁ  ndings to clinical practice, 
however, is limited mainly because of the short duration of 
double-blind studies, which precludes any assessment of 
long-term efﬁ  cacy and chronic adverse effects. Furthermore, 
doses used in regulatory trials do not always reﬂ  ect those 
actually used in clinical practice, and the efﬁ  cacy and safety 
proﬁ  les of patients enrolled in randomized trials may differ 
strikingly from those of patients treated in the daily practice.
Several years ago, we compiled a review of the literature 
on long-term, open studies with gabapentin (GBP), lamotrig-
ine (LTG), levetiracetam (LEV), and topiramate (TPM), 
when used as add-on in drug-resistant epileptic patients.17 In 
that study, we searched for three robust markers of efﬁ  cacy 
or tolerability: the percentage of patients attaining a 6-month, 
seizure-free period; the percentage of patients withdrawing 
because of adverse effects; and the percentage of patients 
continuing treatment. Clear differences between these four 
drugs were observed.
Here, we analyze long-term studies performed with 
ZNS. The markers that we chose for this analysis were: the 
percentage of patients continuing treatment (retention in the 
study), the percentage of responder patients (those patients 
achieving a 50% seizure reduction), the percentage of 
patients attaining seizure freedom for a deﬁ  ned time (at least 
6 months), and percentage of patients withdrawing from the 
study because of adverse effects. While the ﬁ  rst parameter 
is a mixed measure of efﬁ  cacy and tolerability, the second 
and third are pure measures of efﬁ  cacy, and the fourth is 
a pure measure of tolerability. The heterogeneity of the 
selected studies precluded any sophisticated analysis of the 
above-mentioned markers of efﬁ  cacy or tolerability.
Methods
In December 2008, a computer search of Medline (PubMed 
version) was conducted for all articles on ZNS using the 
following Boolean keyword syntax: zonisamide AND 
epilepsy. The Medline search produced 430 articles. Other 
studies were found by manual searching.
We found 41 open studies documenting the clinical evalu-
ation of ZNS in epilepsy. From these articles we selected 
trials that met the following criteria: 1) open-label studies 
performed in epileptic patients to whom ZNS was adminis-
tered as monotherapy or add-on therapy at standard dosages, 
2) the duration of the study was at least 6 months, 3) at least 
one of the outcome measures (see below) had to be reported, 
4) populations of adults and/or children were included. 
Studies speciﬁ  cally aimed at recruiting special populations 
(such as the elderly, intellectually disabled, patients affected 
by speciﬁ  c epileptic syndromes) were excluded.
Outcome measures
Our analysis included those trials that reported at least one 
of the following parameters:
1.  Number and/or percentage of patients continuing the 
experimental treatment for the indicated period of time 
(6 months or longer).
2.  Number and/or percentage of responders (a responder is 
a patient who has a 50% seizure reduction, with respect 
to a baseline seizure frequency). Although some studies 
reported the percentage of patients acquiring 25%, 
and 75% seizure reduction, for our analysis, we con-
sidered only the ﬁ  rst outcome measure.
3.  Number and/or percentage of patients who were seizure-
free for a speciﬁ  c period of time (at least 6 months).
4.  Number and/or percentage of patients who withdrew from 
the study because of adverse effects.
Statistical analyses
The 95% confidence intervals (CI) were calculated to 
estimate the statistical variations of our end-points. Standard 
methods were used to calculate 95% CI of the mean. In 
the case of proportions, the calculation was based on the 
equations described by Fleiss.18
Results
Thirty-two studies were excluded from our analysis because 
they reported on speciﬁ  c epileptic syndromes of infancy, had Neuropsychiatric Disease and Treatment 2009:5 251
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insufﬁ  cient or unspeciﬁ  ed durations, did not use our outcome 
measures for evaluation or for miscellaneous causes (such as 
duplication of data from other studies, utilization of unusual 
dosages, not published in English, French or Italian).
Nine articles were selected for the analysis.19–27 Their 
characteristics and results are summarized in Table 1.
One of the chosen articles was a review20 of long-term 
data from patients who had been recruited in the four key 
ZNS double-blind studies.11–14 From this review, we drew 
information concerning three extension studies (studies 
922 ext, 912 ext, 912–39 ext, all conducted in US). In each 
study, the number of patients included in the open phase was 
reported. Data from the fourth long-term extension study 
included in Leppick’s review has been recently published 
in extenso.21 Therefore, for this study we selected data from 
the last publication only. While it was possible to report 
efﬁ  cacy data for any single extension study, the percentage 
of patients withdrawing for adverse effects was available 
only as cumulative data from all of the double-blind, and 
some open, long-term studies.20 We considered each of 
these evaluations as a separate study. Therefore, the total 
number of clinical studies actually included in our analysis 
was 12. Nine studies were prospective,19–23,26 and three were 
retrospective.24,25,27
The main difference among the selected studies was 
the population of patients recruited. The first group of 
eight studies19–23 was performed in adult, drug-resistant patients, 
mainly with localization-related epilepsies, and in whom ZNS 
was added to a previous AED treatment. Two retrospective 
studies included patients treated with ZNS as monotherapy.24,25 
However, in both studies, the patient population was heteroge-
neous, consisting of newly diagnosed patients and patients who 
were being treated with another AED that was later withdrawn 
due to its ineffectiveness or lack of tolerance.
One prospective study26 included a mixed population of 
pediatric patients treated with ZNS, as an add-on or mono-
therapy. Finally, the last study was retrospective, and the 
percentage of patients on monotherapy or polytherapy was 
not speciﬁ  ed.27
Retention of patients in the trial
Five of the studies provided this information,19–22,24,27 and 
these data, calculated at different time points, are reported 
in Figure 1. In all of these studies, ZNS was added in lieu 
of an unsatisfactory AED treatment. We observed that the 
percentages of patients who continued to use this drug after 
1 year ranged between 50% and 60%, with a modest drop-
off over time.
Percentage of responders
The percentages of patients achieving a 50% seizure 
reduction, with respect to a baseline seizure frequency, was 
calculated for each of the seven studies,20,21,23,24,26 and is repre-
sented in Figure 2. We observed that, in those studies where 
ZNS was added to a previous therapy,20,21,23 percentages of 
responders were between 37% and 50%. In those studies 
performed on mixed populations of patients24,26 (patients 
mainly on monotherapy with presumably less severe forms 
of epilepsy), percentages of responders were higher (between 
60% and 65%).
Patients who were seizure-free
The percentage of patients reaching seizure freedom was 
given in three studies.21,24,25 However, one study calculated 
this parameter in a manner that was different to the other two. 
The ﬁ  rst study,21 conducted on a population of drug-resistant 
patients, considered those patients who did not have seizures 
for a period of 6 or 12 months during the study, and at the 
end of the observation period (terminal seizure freedom) 
(Table 1). The two remaining studies,24,25 in which ZNS was 
given as a monotherapy, considered those patients who had 
been free of seizures for at least 6 months, to be 6-months 
seizure-free.
Patients who discontinued the study 
due to adverse effects
The percentage of patients who discontinued the experimental 
drug because of adverse effects were reported in seven 
clinical studies19,20,22–25,27 and were between 4% and 25% 
(see Figure 3). It was evident that these seven studies, which 
were long-term extensions of double-blind studies, had 
dropout rates that were generally higher than prospective-
open studies.
Discussion
Efﬁ  cacy and tolerability of ZNS have been demonstrated in 
four double-blind, placebo-controlled, multicenter trials.11–14 
In these studies, about 800 patients with drug-resistant forms 
of epilepsy received ZNS for a period of 6 months. The 
overall results of these studies showed that ZNS was effective 
at doses of 300 to 500 mg/day, although it was suggested that 
lower doses may be beneﬁ  cial for some patients.28 Treat-
ment-related adverse events were mostly mild to moderate 
in severity and resulted in few discontinuations. In fact, 
only 19.3% of patients withdrew due to adverse side effects, 
compared with 8.6% of placebo-treated patients.28Neuropsychiatric Disease and Treatment 2009:5 252
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Long-term zonisamide use in epilepsy
However, the transferability of ﬁ  ndings obtained from 
these double-blind studies to clinical practice, is limited by 
several factors. First, the doses used did not reﬂ  ect the actual 
ones used in clinical practice. For example, in two studies, 
ZNS doses were ﬁ  xed and some patients were randomized 
to a dose, which were ineffective.11 This may have led to an 
apparently low overall efﬁ  cacy.16 Second, the efﬁ  cacy and 
safety proﬁ  les in patients enrolled in randomized trials may 
differ from those of patients treated in everyday practice. 
Finally, the follow up period of these double-blind studies 
was short, being 6 months.
Since epilepsy is a chronic disease, in the majority of 
cases AEDs must be taken for years and often for the life 
of a patient; thus, further studies are necessary to ascertain 
whether a treatment will maintain its efﬁ  cacy and tolerability 
over the long-term.
The analysis of long-term, open-label studies is a useful 
way to provide this crucial information.
In our review, we included studies performed in different 
populations of patients. It has been reported that the range 
of patients with newly diagnosed epilepsies and whose 
seizures are completely controlled by a ﬁ  rst AED, is 50% 
to 60%. In those patients who continue to have seizures 
despite multiple, appropriate drug treatments, the chance of 
becoming seizure-free when a new AED is added is lower 
than 5%.29 For this reason, clinical data from add-on studies 
must be discussed apart from those where this drug was used 
as monotherapy.
Long-term, add-on, studies performed 
in patients with drug-resistant epilepsies
These studies were all prospective and were often open, 
long-term extension studies of previous double-blind studies.20,21 
Three studies19,22,23 were not extensions of controlled studies, 
but were each performed in similar populations of drug-
resistant patients. A retrospective study was performed, at least 
in part, in a presumably similar population of patients.27
Retention data, available only for some of these 
studies,19,21,22,27 showed that the percentages of patients 
continuing treatment with the experimental drug after 1 year 
were between 60% and 70%, with only a modest decrease 
over time. Data from other AEDs,17 in similar populations 
of patients, showed that after 1 year, retention of GBP was 
very low, at 25%, while LTG had retention values between 
40% and 60%, TPM retention was around 55%, and LEV, 
which had the best scores, had retention values between 60% 
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and 80%. Therefore ZNS, in regard to this mixed measure of 
efﬁ  cacy and tolerability, had a performance similar to that 
of most effective AEDs.
The purest measure of   efﬁ  cacy is the percentage of   
patients who reached a seizure-free state for a certain period 
of time. In a previous analysis,17 we considered those patients 
who did not have seizures for 6 months to be seizure-free; 
this evaluation, was reported in three studies (Table 1).21,24,25 
One of these studies, however, included a population of 
patients who were not controlled with the appropriate AED 
treatment. In this study,21 about 9% of patients acquired a 
6-month period of seizure freedom, but only 2% of patients 
were seizure-free in the last 6 months (terminal seizure 
freedom). Data obtained from a study of other AEDs,17 
reported that GBP and LTG were associated with 6-month 
seizure-freedom rates below 4%, while TPM had seizure-
free rates around 8% and LEV about 13%. However, the 
method used for calculating seizure freedom may inﬂ  uence 
the result. In fact, as the duration of a study increases, so does 
the probability of acquiring seizure freedom for the speciﬁ  ed 
period of 6 months; and the probability of attaining terminal 
6-month seizure freedom is stable.
In this review we have also considered another, less 
robust, measure of efﬁ  cacy: percentage of patients achieving 
a reduction in seizure frequency of 50%, with respect to 
baseline. Findings from studies on drug-resistant patients 
who reported this outcome measure20,21,23 (Figure 2) to be 
between 35% and 50%, allowed comparison with double-
blind studies where similar parameters were evaluated. In 
a review of all double-blind studies,28 similar values were 
observed when patients were randomized to a ZNS dose 
of 300 to 500 mg/day. This ﬁ  nding conﬁ  rmed data from 
controlled studies and indicated that ZNS maintained its 
efﬁ  cacy over time.
With regards to tolerability in populations of patients with 
drug-resistant epilepsies, we found (Figure 3) that in some 
studies,19,20,22,23,27 the percentage of patients withdrawing from 
the experimental drug was around 25%, while other studies 
reported lower percentages. We can speculate that, at least 
in some cases, this difference may be a consequence of the 
titration scheme. In fact, the long-term studies which were 
extensions of previous double-blind studies20 (in double-
blind studies a ﬁ  xed-titration scheme and a high maintenance 
dose has to be reached) had higher withdrawal rates than 
those studies in which a low standard initial dose was used, 
and where titration speed and ﬁ  nal doses were individually 
adjusted. In two of these studies,22,23 fewer than 10% of 
patients withdrew because of adverse effects. Similar studies 
performed with other AEDs found percentages around 28% 
for TPM, and lower for GBP, LTG and LEV (18%, 15%, 
and 13% respectively).17
Long-term studies performed in patients 
on monotherapy
Data about efﬁ  cacy and tolerability of ZNS administered 
as monotherapy was derived from four studies. Due to 
heterogeneity of patients recruited and treatment admin-
istered, only some of the data could be used in our study. 
Two retrospective studies24,25 included patients with newly 
diagnosed epilepsies and patients who discontinued treat-
ment with a previously unsatisfactory AED (for inefﬁ  cacy 
or lack of tolerability). It was reported that the percentage 
of patients with newly diagnosed epilepsies, whose seizures 
were completely controlled by the ﬁ  rst AED used, ranged 
between 50% and 60%.When the ﬁ  rst AED was ineffective, 
the chance of a second AED being fully effective was about 
10%.29,30 Two other studies26,27 included patients treated with 
ZNS as an add-on and monotherapy. The studies did not 
provide separate analyses.
Data about retention was reported in one study only.27 
This included patients on both monotherapy and polytherapy, 
with unknown percentages, and was a retrospective mono-
therapy study. Results, already discussed in the previous 
section, did not give information on ZNS effectiveness when 
this drug was administered as a monotherapy. The percentage 
of patients on monotherapy who acquired seizure freedom 
for at least 6 months was reported in two studies.24,25 In 
both cases, they (between 24% and 26%) were higher than 
that usually observed in drug-resistant patients, but much 
lower than that found when a new drug was administered to 
newly diagnosed patients.29,30 The result probably reﬂ  ects the 
heterogeneity of the studied population.
Responder rates were calculated in two studies24,26 and 
ranged between 60% and 65%. This, too, may reﬂ  ect the 
heterogeneity of the populations included in these studies. 
Finally, the percentage of patients withdrawing because of 
adverse effects was low in both monotherapy studies,24,25 but 
was higher in one study with a mixed population of patients 
on add-on or monotherapy ZNS treatment. The limited 
amount, and the heterogeneity, of data did not allow us to 
draw deﬁ  nitive conclusions on efﬁ  cacy and tolerability of 
ZNS administered as monotherapy.
Long-term adverse effects of zonisamide
From the analysis of double-blind controlled studies emerges 
a favorable ZNS tolerability proﬁ  le.16 In a meta-analysis Neuropsychiatric Disease and Treatment 2009:5 257
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of all adverse effects observed with new AEDs in key, 
placebo-controlled clinical studies, ZNS and GBP signiﬁ  cantly 
associated with two adverse effects (somnolence and dizziness), 
while LEV associated with one adverse effect; all other AEDs 
signiﬁ  cantly associated with three or four adverse effects.31
In Table 2, the adverse effects most frequently observed in 
some long-term studies are reported.19,20,21,22 Somnolence and 
dizziness were the most frequently observed adverse effects.
Adverse effects characteristic of ZNS and TPM, included 
anorexia and/or decreased appetite. These effects generally 
caused a small amount of weight loss, which did not appear to 
be progressive and stabilized over period of 2 years.20 In some 
controlled studies,12,13 a small percentage of patients developed 
cognitive problems during short-term ZNS treatment. Table 2 
shows that adverse effects were also observed during long-
term treatment. These effects were usually related to dose and 
titration speed.20,32 To speciﬁ  cally address long-term effects of 
different doses of ZNS on cognition, an assessment of several 
cognitive functions was performed in epileptic patients 
before, and after 1 year of ZNS treatment. It was observed 
that some cognitive functions, such as delayed word recall 
and verbal ﬂ  uency, were adversely affected by ZNS after 
1 year of treatment, and that the effect was more pronounced 
at higher doses.33
Kidney stones, a relatively rare complication of ZNS, 
were reported in about 4% of chronically treated patients.34 
In Leppik’s study,19 which is the oldest long-term study, 
kidney stones were observed in 3.5% of their patients. Other 
less frequently reported, and often idiosyncratic, adverse 
effects do not always emerge from the analysis of clinical 
studies. Oligohydrosis was reported in one study only,22 and 
may be rarely caused by ZNS.1,5,8 The suggested mechanism 
may be the weak inhibition of carbonic anhydrase by ZNS. 
In a small percentage of cases (between 1.4% in USA and 
Europe, and 2% in Japan), a cutaneous rash, leading to 
drug discontinuation, was associated with ZNS treatment. 
Table 2 Selection of the most important adverse effects in some clinical studies
Adverse effect Leppik20* Wroe et al21* Leppik et al19*,& Shinnar et al22**
Number of patients included 
in the study
N = 1207 N = 318 N = 113 N = 109
Drowsiness or somnolence 263 (21.8%) 47 (14.8%) 15 (13.3%) 22 (20.2%)
Dizziness 247 (20.5%) 54 (17%) 18 (15.9%) 4 (3.7%)
Anorexia or decreased 
appetite
201 (16.7%) 17 (15%) 20 (18.3%)
Fatigue or tiredness or 
asthenia
182 (15.1%) 39 (12.3%) 10 (8.8%) 5 (4.6%)
Nausea 159 (13.2%) 35 (11%) 17 (15%)
Headache 145 (12%) 74 (23.3%) 18 (15.9%)
Disturbance in attention or 
confusional states
145 (12%) 12 (10.6%)
Mental slowing 138 (11.4%)
Thinking abnormal 11 (9.7%) 5 (4.6%)
Behavioral changes or 
epileptic psychosis, irritability, 
agitation, nervousness,
133 (11%) 10 (8.8%) 9 (8.3%)
Hostility 9 (8.3%)
Emotional lability 6 (5.5%)
Diplopia 131 (10.9%)
Difﬁ  culty with memory 125 (10.4%)
Weight loss 43 (13.5%)
Diarrhea 33 (10.4%)
Ataxia 12 (10.6%)
Dysarthria 10 (8.8%)
Decreased sweating       8 (7.3%)
*Adverse events reported by 10% of patients. 
&Adverse events observed during long-term phase only in patients enrolled in the long-term study.
**Adverse events reported by 2% of patients.Neuropsychiatric Disease and Treatment 2009:5 258
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Interestingly, this rash was more frequently observed in 
patients on monotherapy than in patients on polytherapy.8,35. 
Low incidences of serious skin reactions, such as Stevens-
Johnson syndrome and toxic epidermal necrolysis, have been 
reported by post-marketing experiences from Japan.20,36
In conclusion, ZNS is a new AED, which has been 
approved in the USA and Europe as adjunctive therapy 
for epileptic patients who are refractory to monotherapy. 
Among all other new AEDs which have been approved for 
this indication, ZNS should be considered because it has a 
predictable pharmacokinetic proﬁ  le, allowing once- or twice-
daily dosing, and no clinically relevant interactions with other 
ﬁ  rst-line AEDs. Also, this drug has multiple mechanisms 
of action, which beget two important advantages: a broad 
spectrum of action in the ﬁ  eld of epilepsy and possible 
effects on other neurological or psychiatric diseases. Uncon-
trolled data suggest that beneﬁ  cial effects extend across a 
range of seizure types and syndromes including generalized 
epilepsy,37 juvenile myoclonic epilepsy, and progressive 
myoclonic epilepsy.36
ZNS is also under evaluation for the treatment of several 
other diseases. To date, controlled studies have shown that 
at doses of 25 to 100 mg/day, it is an effective adjunctive 
treatment in patients with Parkinson disease.38 ZNS is also 
being tested for treatment of essential tremors.39,40 Since ZNS, 
like TPM, is associated with weight loss, trials have also 
been performed in obese patients41 and patients with binge 
eating disorder, with interesting results.42,43 Preliminary data 
suggest that ZNS may be effective for prophylactic treatment 
in patients with bipolar disorders.44 Finally, one open study 
showed that this drug may be a safe and effective adjunctive 
agent for migraine prevention,45 while one controlled study 
failed to show clinically signiﬁ  cant results in patients with 
painful, diabetic neuropathies.46
Epilepsy is a chronic condition that may be associated 
with several other diseases.47 In patients who display other 
diseases in association with epilepsy, the availability of a 
drug that exerts a positive effect on the comorbid disease 
may be of strategic importance for optimizing therapy on 
an individual basis.48
Our review of long-term studies shows that ZNS main-
tains its efﬁ  cacy and has good tolerability over time. It may 
therefore be a good choice as an add-on treatment in epileptic 
patients where other AEDs have produced unsatisfactory 
results.
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